Thermo Fisher Scientific and AstraZeneca sign NGS-based CDx co-development agreement
![](/46/pdcnewsitem/11/39/84/HLN00CPO_Thermo_Fisher990x525_scaled.jpg)
Companies say earlier collaboration may speed development and introduction of targeted precision medicine therapies for patients.
Thermo Fisher Scientific and AstraZeneca have signed a multi-year, global agreement to co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support the Anglo-Swedish pharma firm's portfolio of targeted therapies, the two companies said on Wednesday.
NGS-based companion diagnostics are increasingly used to match patients with new therapies for cancer and other diseases. More than 90% of AstraZeneca's clinical pipeline, including main areas such as oncology, cardiovascular and renal, metabolic, and respiratory disease, are targeted precision medicine therapies.
Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific said that as the pipeline of targeted therapies expands, the availability of diagnostic tools that can interrogate multiple biomarkers simultaneously will ensure patients can be matched with the right therapies more quickly.
"Introduction of diagnostic tools early in the process of drug development can further facilitate the success of companion diagnostic development - and that's what we're doing with AstraZeneca," he added.
Ruth March, senior vice president, precision medicine and biosamples, AstraZeneca said the collaboration offers the technology, expertise and ability to decentralize CDx tests to local healthcare providers across the company's global markets, "which will help us identify more patients around the world who may benefit from treatments and effective patient care."
Thermo Fisher currently offers the only globally distributable NGS CDx solution approved and reimbursed by government and commercial insurers in more than 15 countries, including the US, Europe, Japan, South Korea and the Middle East.
![Thermo Fisher Scientific Inc.](https://www.cphi-online.com/c248503th_S-comp248503.jpg)
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance